Preclinical studies with T-474 and T-418, two structurally distinct CDK8/CDK19 inhibitors, demonstrated induction of prostate cancer cell death and significant anti-tumour activity in CRPC xenografts [137]. This evidence concerns the gene CDK8 and prostate carcinoma.